- Active not recruitingPHASE3
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
This study is looking at a new medicine called ALXN1850 for children with a rare bone condition called hypophosphatasia (HPP). It compares ALXN1850 with a current treatment, asfotase alfa, to see if it's safe and works well for children who have already been using asfotase alfa.
For: HypophosphatasiaUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic use (Phase IV)
An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)
This study looks at ways to help a medicine called Asfotase Alfa (STRENSIQ®) work better for people with Hypophosphatasia. Sometimes the body fights this medicine, so the study tests other treatments to stop that and improve how well the medicine works.
For: HYPOPHOSPHATASIAFrance